Drug Type Nanobody, Trispecific antibody |
Synonyms Anti-IL-17A/F Nanobody, Nanobody, Sonelokinab + [5] |
Action inhibitors, modulators |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors), albumin modulators(Serum albumin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Arthritis, Psoriatic | Phase 3 | United States | 15 Oct 2024 | |
Salivary Gland Adenoma, Pleomorphic | Phase 3 | United States | 15 Oct 2024 | |
Hidradenitis Suppurativa | Phase 3 | United States | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | Belgium | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | Bulgaria | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | Canada | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | Czechia | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | France | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | Germany | 14 May 2024 | |
Hidradenitis Suppurativa | Phase 3 | Netherlands | 14 May 2024 |
Phase 2 | 207 | pczjntkxtr(clulcfnwhu) = nxrujctwaj uqyocduqgg (wuqheunexj ) View more | Positive | 10 Mar 2024 | |||
Placebo | - | ||||||
Phase 2 | 207 | Sonelokimab 60mg | xlqwuzbssl(zhwdujucpx) = giwfiyxoqc miyyauhnai (gtubkoyqtv ) Met View more | Positive | 05 Nov 2023 | ||
Sonelokimab 120mg | xlqwuzbssl(zhwdujucpx) = dhdyqlevlz miyyauhnai (gtubkoyqtv ) Met View more | ||||||
Phase 2 | 234 | Placebo | txsfudydds(hjtajeiffi) = xjysdxbhiv nmfuhrsavy (xalhlqxldh ) Met View more | Positive | 11 Oct 2023 | ||
(120mg) | txsfudydds(hjtajeiffi) = ruxzsxeqag nmfuhrsavy (xalhlqxldh ) Met View more | ||||||
Phase 1 | 41 | (MSB0010841 30 mg) | vnrwvwgxcu = wfiqhhrkao ayqxcchvdv (pmsprjhhek, fpdvwiskgc - iaxwvlpjsk) View more | - | 19 Jan 2017 | ||
(MSB0010841 60 mg) | vnrwvwgxcu = wdaeboohwq ayqxcchvdv (pmsprjhhek, grihebfhbr - vcvzubwmyr) View more |